Kuida® introduced as first Colombian mass-market CBD Cosmeceutical brand at Cosmoprof

Event attracts up to 200,000 global retail buyers (Source: BolognaFiere Group )

Khiron Skin Unit Director to speak on CBD-based cosmetics expert panel

Global skincare market expected to reach US$131 Billion in 2019

TORONTO, March 5, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that the Company will participate in Cosmoprof Worldwide Bologna, taking place March 14-17 in Bologna, Italy. Recognized as the largest and most important event in the beauty buyers' calendar, this event brings the Company's Kuida® cosmeceutical portfolio to a global network of retail buyers and distributors.

Andres Galofre, Co-founder and VP Business Development, Khiron Life Sciences Corp., states, "Our participation in Cosmoprof Worldwide Bologna marks an important milestone for Khiron as we bring the Kuida® brand to the global market for the first time. As well, we will be educating beauty buyers about cannabis legislation in their jurisdiction as it applies to CBD-based cosmeceuticals, and increase awareness of the market potential in this fast developing category."

Kuida®, the first consumer brand for Khiron's wellness unit, brings the benefits of cannabidol (CBD) to a comprehensive portfolio of skin and body care products for women. Launched in Colombia in October 2018 through retail, wholesale and online channels, Kuida® will now target the global skincare market which, according to Euromonitor International is expected to reach US$131 Billion in 2019.

Elsa Navarro, Skin Unit Director, Khiron life Sciences Corp., states "CBD-based products are rapidly taking centre stage on the global skincare market. With our proven product development and marketing experience it is important for Kuida® to participate in the industry discussion on product innovation, consumer education, legislation, distribution and marketing, in order to assist retail buyers in making informed buying decisions."

Juan Carlos Castro, Director of Cosmetics and Cleanliness Industry at ANDI, the National Business Association of Colombia, commented, "Global trends led by consumers and manufacturers have created opportunity for new technologies and ingredients that can bring wellness benefits, including through the use of cannabis. Khiron has recognized this opportunity and is leading the path in Latin America through the development of their Kuida® consumer brand."

Visit Khiron at Cosmoprof Worldwide Bologna: Hall 14, Extraordinary Gallery booth 26

About BolognaFiere Group

BolognaFiere is one the leading International exhibition organizers and one of the most advanced exhibition centres worldwide.

BolognaFiere Group manages three exhibition centres (Bologna, Modena, and Ferrara) with over 75 outstanding exhibitions in Italy and abroad; BolognaFiere Group consists of several companies than offer an extensive range of events and provide businesses with all of the promotion and specialized services they need to successfully participate in every exhibition. For more information on BolognaFiere Group visit www.bolognafiere.it

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis companies to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/

Cautionary Notes

Market and Industry Data

This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: [email protected]; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: [email protected]